NASDAQ:SRDX - SurModics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$54.80 -0.55 (-0.99 %)
(As of 06/20/2018 03:33 AM ET)
Previous Close$55.35
Today's Range$54.65 - $56.20
52-Week Range$24.25 - $57.75
Volume116,000 shs
Average Volume56,129 shs
Market Capitalization$731.84 million
P/E Ratio108.53
Dividend YieldN/A
Beta0.65
SurModics logoSurmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio2.38
Quick Ratio2.26

Price-To-Earnings

Trailing P/E Ratio108.53
Forward P/E Ratio-2,740.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$73.11 million
Price / Sales9.94
Cash Flow$0.9535 per share
Price / Cash57.47
Book Value$8.41 per share
Price / Book6.52

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$3.92 million
Net Margins1.49%
Return on Equity5.33%
Return on Assets4.18%

Miscellaneous

Employees257
Outstanding Shares13,260,000

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) announced its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.07 EPS for the quarter, beating the Zacks' consensus estimate of ($0.01) by $0.08. The company had revenue of $19.06 million for the quarter, compared to analysts' expectations of $17.92 million. SurModics had a net margin of 1.49% and a return on equity of 5.33%. View SurModics' Earnings History.

What price target have analysts set for SRDX?

5 analysts have issued 1 year price targets for SurModics' stock. Their predictions range from $43.00 to $76.00. On average, they anticipate SurModics' share price to reach $58.00 in the next year. View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. According to Zacks Investment Research, "Surmodics exited the second quarter of fiscal 2018 on a solid note, beating the Zacks Consensus estimate on earnings and revenues. Further, solid performance in the In Vitro Diagnostics segment, which gained grounds on the back of strong growth and stabilization across BioFX, microarray and antigen product sales holds promise. Surmodics issued a solid guidance for fiscal 2018. On the flipside, the company witnessed significantly high operating losses. Product sales declined owing to shipment issues, particularly in the Medical Device segment. Further, foreign-exchange woes related to the Creagh Medical buyout have been a major dampener. Surmodics’ drug-coated balloons face stiff competition in niche space. The company’s margins are expected to be under pressure, due to expenses in the Irish facility infrastructure and lower Medical-Device product gross margins." (5/7/2018)
  • 2. Barrington Research analysts commented, "We are now modeling adjusted FY/18 adjusted EPS of $(0.02) and revenue of $78.4 million. DCB: Patient enrollment for the company’s TRANSCEND pivotal clinical trial continues and about half of U.S.-based clinical sites have now been activated. As a reminder, the trial to treat peripheral artery disease in the upper leg will be randomized and is expected to include 446 patients at up to 60 clinical sites in the U.S. and 18 sites in Europe. It will feature a head-to-head comparison with a competitor’s already commercialized drug-coated balloon product 510(k) products: Surmodics has now received FDA approvals for its first three 510(k) products (two balloon catheters and a microcatheter). Management remains hopeful that it will enter into partnership for all three products over the next two to four quarters Recommendation: We are maintaining our OUTPERFORM investment rating on SRDX shares. Our new price target is $43, up from our previous $38." (5/3/2018)
  • 3. Needham & Company LLC analysts commented, "SRDX is undergoing a transition from a supplier of medical device coatings to finished medical device products. In the near-term, this requires heavy R&D investment which has turned SRDX unprofitable. In the long-term, this should expand SRDX’s available market and accelerate its revenue growth. We believe that investors receive an inexpensive call option on SRDX’s DCBs at its current valuation. Given this, we are initiating coverage with a Buy rating." (2/27/2018)

Who are some of SurModics' key competitors?

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 55)
  • Mr. Andrew D. C. LaFrence CPA, VP of Fin. & Information Systems, CFO and Principal Accounting Officer (Age 55)
  • Mr. Bryan K. Phillips, Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec. (Age 47)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 54)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 52)

Has SurModics been receiving favorable news coverage?

Media stories about SRDX stock have been trending somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SurModics earned a media sentiment score of -0.02 on Accern's scale. They also assigned media headlines about the company an impact score of 40.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are SurModics' major shareholders?

SurModics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.71%), Trigran Investments Inc. (10.40%), Northern Trust Corp (1.39%), Disciplined Growth Investors Inc. MN (1.34%), Millennium Management LLC (1.26%) and Allianz Asset Management GmbH (0.76%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics.

Which institutional investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., State Board of Administration of Florida Retirement System, Citigroup Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Prudential Financial Inc. and American International Group Inc.. Company insiders that have sold SurModics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Jose H Bedoya, Joseph J Stich and Timothy J Arens. View Insider Buying and Selling for SurModics.

Which institutional investors are buying SurModics stock?

SRDX stock was purchased by a variety of institutional investors in the last quarter, including Trigran Investments Inc., BlackRock Inc., EAM Global Investors LLC, Algert Global LLC, Chicago Equity Partners LLC, Matarin Capital Management LLC, Barclays PLC and Northern Trust Corp. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $54.80.

How big of a company is SurModics?

SurModics has a market capitalization of $731.84 million and generates $73.11 million in revenue each year. The company earns $3.92 million in net income (profit) each year or $0.51 on an earnings per share basis. SurModics employs 257 workers across the globe.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for SurModics (SRDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.